Roche ditches final PhIII for cancer hopeful, reports setback for key drug in $1.4B buyout

02 Feb 2023
endpts.com
Phase 3Phase 1Phase 2Clinical Trial TerminationClinical Trial Failure
Over the past few years, Roche has released news about its AKT inhibitorAKT inhibitor ipatasertib in drips — most of them negative. The drug yielded mixed data in a key prostate cancer trial, Phase III flops in triple-negative breast cancer forced the pharma giant to pull the plug there, and in mid-2022 Roche trimmed two more early-stage indications in prostate cancer after completing the trials. Now, the last piece of the program is gone. Roche is officially scrapping the combination of ipatasertib and abiraterone, which was in a Phase III trial for first-line castration-resistant prostate cancer. It’s one of several late-stage programs Roche is sweeping out of the pipeline in its Q4 housecleaning exercise, alongside a trio of Tecentriq combos, the failed Alzheimer’s candidate gantenerumab and a drug for idiopathic pulmonary fibrosis. Separately, the company is dropping a Phase I compound for acute graft-versus-host disease. A Roche spokesperson confirmed to Endpoints News that “we don’t have any further projects ongoing with ipatasertib.” Although the Phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival in June 2020, it missed the key endpoint of overall survival at the second interim analysis. The spokesperson added that the safety profile of the ipatasertib/abiraterone combo was consistent with that observed at the primary analysis. Designed to block the PI3K/AKT pathway, ipatasertib arose from a partnership that Roche’s Genentech struck with Array BioPharma before Pfizer bought them out, and once inspired high hopes as a targeted approach. In the same presentation, Roche disclosed that it slammed the brakes on a Phase III study in idiopathic pulmonary fibrosis after a recent futility analysis suggested it’s unlikely to meet the primary endpoint. RG6354, which is also dubbed PRM-151 or zinpentraxin alfa, was the lead drug from Roche’s 2019 buyout of Promedior , for which it paid $390 million in cash upfront. Despite the setback, Roche still lists that program as a potential drug for myelofibrosis, with a filing expected in 2025 or later. Then there are three Phase III trials for the PD-L1 inhibitorPD-L1 inhibitor Tecentriq being cut, in frontline metastatic urothelial carcinoma (Tecentriq + chemo), second-line non-small cell lung cancer (Tecentriq + Cabometyx) and second-line HER2-positive, PD-L1-positive metastatic breast cancerPD-L1-positive metastatic breast cancer (Tecentriq + Kadcyla), respectively. Also exiting the pipeline are trials for gantenerumab, an anti-amyloid antibody, in preclinical Alzheimer’s and prodromal to mild Alzheimer’s — a reflection of Roche’s previously disclosed decision to stop all studies in the wake of a Phase III failure . Finally, Roche said it’s shutting down an IL-22 fusion protein, known as RG7880 or efmarodocokin alfa, that was being tested for the prevention of acute graft-versus-host disease in patients undergoing bone marrow transplant. The spokesperson cited “strategic reasons” for discontinuing the development, noting that “safety did not play any part in this decision.” Data from the Phase Ib study will be published.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.